- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03184064
Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia (Glu-FX)
Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia: The Glu-FX Study
Study Overview
Status
Conditions
Detailed Description
Intake of carbohydrate-rich foods transiently increases blood glucose levels (known as postprandial glycaemia). Repeated high postprandial glucose responses are evidenced to dysregulate functional proteins, oxidative stress and pancreatic beta cell function; thus increasing the risk of diabetes and cardiovascular disease. Accordingly, meals that elicit a reduced, or more gradual, rise in blood glucose levels are desirable. Fruit polyphenols may help to limit the glucose excursion following a high carbohydrate meal. Previous research by our group has demonstrated that blackcurrant polyphenols significantly inhibited the average incremental area under the curve (T+0 to +30 min) of plasma glucose. Possible mechanisms include inhibition of intestinal enzymes and inhibition of intestinal glucose absorption by decreasing Sodium-glucose linked transporter 1 (SGLT-1) / Glucose transporter 2 (GLUT-2) glucose transporter activity. In vitro data suggests that citrus polyphenols may impact on carbohydrate metabolism by binding to starch molecules, however, effects on postprandial glycaemia are not yet known. Blackcurrants and citrus fruits have distinct polyphenol profiles and may therefore act on glucose homeostasis via different mechanisms. Blackcurrants are rich in anthocyanins and flavanols, whereas citrus fruits are rich in flavanones, hesperetin and naringenin. Theoretically, combining blackcurrant with citrus extracts may have synergistic effects.
The aim of this study is to investigate the effects of blackcurrant polyphenol extracts and citrus polyphenol extracts (and their combination), on postprandial glycaemia, insulinaemia and gastrointestinal hormone concentrations following a mixed carbohydrate test meal. It is hypothesised that blackcurrant and citrus extracts alone will inhibit glycaemia compared to placebo, a combination of the two will have a greater effect.
Study design: A randomised, controlled, double-blind, cross-over study will be conducted. Subjects will consume different drinks at 4 separate study visits. Drinks will contain either: blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose), blackcurrant and citrus extract (low dose + low dose), or placebo (no polyphenols). The study will utilise an incomplete block design. Subjects will consume the placebo drink and 3 out of 4 of the polyphenol-containing drinks during the study. At least a 7-day wash-out period will be required between study days. Baseline (fasted) blood samples will be taken in duplicate at T-10 min and T-5 min before consuming the test drink (T+0 min). Immediately following consumption of the drink, a mixed carbohydrate test meal will be consumed. Further blood samples will be collected at 10 min intervals for the first 30 min and then every 15 min until T+90 min and at T+120 min. Blood samples will be analysed for plasma glucose, insulin, glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), C-peptide and nonesterified fatty acids (NEFA).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
England
-
London, England, United Kingdom, SE1 9NH
- Metabolic Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-70 years
- Men and women
- Healthy (free of diagnosed diseases listed in the exclusion criteria)
- Body Mass Index 18-35 kg/m2
- Able to understand the information sheet and willing to comply with study protocol
- Able to give informed written consent
Exclusion Criteria:
- Those diagnosed with Phenylketonuria (PKU)
- Those with known or suspected food intolerances, allergies or hypersensitivity
- Women who are known to be pregnant or who are intending to become pregnant over the course of the study
- Women who are breast feeding
- Participation in another clinical trial
- Those who have donated blood within 3 months of the screening visit and participants for whom participation in this study would result in having donated more than 1500 millilitres of blood in the previous 12 months.
- Full Blood Counts and Liver Function test results outside of the normal range.
- Current smokers, or reported giving up smoking within the last 6 months
- History of substance abuse or alcoholism
- Reported history of Cardiovascular disease, diabetes (or fasting glucose ≥ 7.1 mmol/L), cancer, kidney, liver or bowel disease, gastrointestinal disorder or use of drug likely to alter gastrointestinal function
- Unwilling to restrict consumption of specified high polyphenol foods for 48 h before the study
- Weight change >3kg in preceding 2 months
- Blood pressure ≥160/100 mmHg
- Total cholesterol ≥ 7.5 mmol/L; fasting triacylglycerol concentrations ≥ 5.0 mmol/L
- Medications that may interfere with the study: alpha-glucosidase inhibitors (acarbose: Glucobay), insulin sensitizing drugs (metformin: Glucophage, Glucophage SR, Eucreas, Janumet; thiazolidinediones: Actos, Competact), sulfonylureas (Daonil, Diamicron, Diamicron MR, Glibenese, Minodiab, Amaryl Tolbutamide), and lipid lowering drugs (statins, nicotinic acid, colestyramine anhydrous, ezetimibe, fibrates). Other medications should be reviewed by medical representative from KCL on a case by case basis.
- Nutritional supplements that may interfere with the study: higher dose vitamins/minerals (>200% Recommend Nutrient Intake), B vitamins, Vitamin C, calcium, copper, chromium, iodine, iron, magnesium, manganese, phosphorus, potassium and zinc. Subjects already taking vitamin or minerals at a dose around 100% or less up to 200% of the RNI, or evening primrose/algal/fish oil supplements will be asked to maintain habitual intake patterns, ensuring that they take them every day and not sporadically. They will be advised not to stop taking supplements or start taking new supplements during the course of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment arm 1
Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order.
Visits will be separated by at least 7 days.
|
Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
|
EXPERIMENTAL: Treatment arm 2
Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order.
Visits will be separated by at least 7 days.
|
Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
|
EXPERIMENTAL: Treatment arm 3
Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order.
Visits will be separated by at least 7 days.
|
Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
|
EXPERIMENTAL: Treatment arm 4
Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order.
Visits will be separated by at least 7 days.
|
Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postprandial glycaemia (iAUC 0-30 min)
Time Frame: 30 min
|
The primary endpoint is iAUC 0-30 min for plasma glucose concentrations
|
30 min
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postprandial glycaemia: iAUC 0-120 min
Time Frame: 120 min
|
iAUC 0-120 min for plasma glucose concentrations
|
120 min
|
Postprandial glycaemia: iCmax
Time Frame: 120 min
|
iCmax for plasma glucose concentrations
|
120 min
|
Postprandial glycaemia: Tmax
Time Frame: 120 min
|
Tmax for plasma glucose concentrations
|
120 min
|
Postprandial glycaemia: absolute concentrations at specific time points
Time Frame: 120 min
|
Absolute concentrations at specific time points, for plasma glucose concentrations
|
120 min
|
Postprandial insulinemia: iAUC 0-30 min
Time Frame: 30 min
|
iAUC 0-30 min for serum insulin concentrations
|
30 min
|
Postprandial insulinemia: iAUC 0-120 min
Time Frame: 120 min
|
iAUC 0-120 min for serum insulin concentrations
|
120 min
|
Postprandial insulinemia: iCmax
Time Frame: 120 min
|
iCmax, for serum insulin concentrations
|
120 min
|
Postprandial insulinemia: Tmax
Time Frame: 120 min
|
Tmax for serum insulin concentrations
|
120 min
|
Postprandial insulinemia: absolute concentrations at specific time points
Time Frame: 120 min
|
Absolute concentrations at specific time points, for serum insulin concentrations
|
120 min
|
Postprandial C-peptide: iAUC 0-30 min
Time Frame: 30 min
|
iAUC 0-30 min for plasma C-peptide concentrations
|
30 min
|
Postprandial C-peptide: iAUC 0-120 min
Time Frame: 30 min
|
iAUC 0-120 min for plasma C-peptide concentrations
|
30 min
|
Postprandial C-peptide: iCmax
Time Frame: 120 min
|
iCmax for plasma C-peptide concentrations
|
120 min
|
Postprandial C-peptide: Tmax
Time Frame: 120 min
|
Tmax for plasma C-peptide concentrations
|
120 min
|
Postprandial C-peptide: Absolute concentrations at specific time points
Time Frame: 120 min
|
Absolute concentrations at specific time points, for plasma C-peptide concentrations
|
120 min
|
Postprandial non-esterified fatty acids (NEFA): iAUC 0-30 min
Time Frame: 30 min
|
iAUC 0-30 min for serum NEFA concentrations
|
30 min
|
Postprandial non-esterified fatty acids (NEFA): iAUC 0-120 min
Time Frame: 120 min
|
iAUC 0-120 min for serum NEFA concentrations
|
120 min
|
Postprandial non-esterified fatty acids (NEFA): iCmax
Time Frame: 120 min
|
iCmax for serum NEFA concentrations
|
120 min
|
Postprandial non-esterified fatty acids (NEFA): Tmax
Time Frame: 120 min
|
Tmax for serum NEFA concentrations
|
120 min
|
Postprandial non-esterified fatty acids (NEFA): Absolute concentrations at specific time points
Time Frame: 120 min
|
Absolute concentrations at specific time points, for serum NEFA concentrations
|
120 min
|
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-30 min
Time Frame: 30 min
|
iAUC 0-30 min for plasma GIP concentrations
|
30 min
|
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-120 min
Time Frame: 120 min
|
iAUC 0-120 min for plasma GIP concentrations
|
120 min
|
Postprandial blood glucose-dependent insulinotropic peptide (GIP): iCmax
Time Frame: 120 min
|
iCmax, for plasma GIP concentrations
|
120 min
|
Postprandial blood glucose-dependent insulinotropic peptide (GIP): Tmax
Time Frame: 120 min
|
Tmax for plasma GIP concentrations
|
120 min
|
Postprandial blood glucose-dependent insulinotropic peptide (GIP): Absolute concentrations at specific time points
Time Frame: 120 min
|
Absolute concentrations at specific time points, for plasma GIP concentrations
|
120 min
|
Postprandial blood Glucagon-like peptide 1 (GLP-1): iAUC 0-30 min
Time Frame: 30 min
|
iAUC 0-30 min for plasma GLP-1 concentrations
|
30 min
|
Postprandial blood Glucagon-like peptide 1 (GLP-1): iAUC 0-120 min
Time Frame: 120 min
|
iAUC 0-120 min, for plasma GLP-1 concentrations
|
120 min
|
Postprandial blood Glucagon-like peptide 1 (GLP-1): iCmax
Time Frame: 120 min
|
iCmax for plasma GLP-1 concentrations
|
120 min
|
Postprandial blood Glucagon-like peptide 1 (GLP-1): Tmax
Time Frame: 30 min
|
Tmax for plasma GLP-1 concentrations
|
30 min
|
Postprandial blood Glucagon-like peptide 1 (GLP-1): Absolute concentrations at specific time points
Time Frame: 120 min
|
Absolute concentrations at specific time points, for plasma GLP-1 concentrations
|
120 min
|
Postprandial blood peptide YY (PYY): iAUC 0-30 min
Time Frame: 30 min
|
iAUC 0-30 min for plasma PYY concentrations
|
30 min
|
Postprandial blood peptide YY (PYY): iAUC 0-120 min
Time Frame: 120 min
|
iAUC 0-120 minfor plasma PYY concentrations
|
120 min
|
Postprandial blood peptide YY (PYY): iCmax
Time Frame: 120 min
|
iCmax for plasma PYY concentrations
|
120 min
|
Postprandial blood peptide YY (PYY): Tmax
Time Frame: 120 min
|
Tmax for plasma PYY concentrations
|
120 min
|
Postprandial blood peptide YY (PYY): Absolute concentrations at specific time points
Time Frame: 120 min
|
Absolute concentrations at specific time points, for plasma PYY concentrations
|
120 min
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Food diary (estimated/unweighed)
Time Frame: 7-days, collected at screening
|
Habitual dietary intake analysis
|
7-days, collected at screening
|
VAS measures of the palatability of the study drink
Time Frame: 10 min following the test drink
|
Descriptive statistics
|
10 min following the test drink
|
VAS measures of mood, satiety and digestive comfort
Time Frame: 120 min
|
Descriptive statistics
|
120 min
|
Buccal mouth swab
Time Frame: One off sample, collected at screening
|
Future exploratory analysis of lactase activity via the derived allele at the European lactase persistence (LP) locus
|
One off sample, collected at screening
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HVS-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postprandial Period
-
King's College LondonBiotechnology and Biological Sciences Research Council; Quadram Institute Bioscience and other collaboratorsCompletedPostprandial PeriodUnited Kingdom
-
Lucozade Ribena SuntoryKing's College LondonCompletedEffect of Drinks Containing Fruit Polyphenol Extracts and Fibre on Postprandial Glycaemia. (Glu-MIX)Postprandial PeriodUnited Kingdom
-
University of BergenHaukeland University HospitalCompletedBiomarkers | Postprandial Period | FastingNorway
-
King's College LondonRoyal Veterinary CollegeCompletedPostprandial Period | Lipemia | Vasodilation | Vascular Resistance | Nitric OxideUnited Kingdom
-
Augusta UniversityRecruitingSpinal Cord Stimulator Trial Period, Neuromodulation Trial Period, SCS Trial PeriodUnited States
-
Northumbria UniversityCompletedAppetite | Postprandial Glycaemia, | Postprandial InsulinaemiaUnited Kingdom
-
Solvay PharmaceuticalsCompletedPostprandial Bloating | Postprandial Belching | Postprandial EructationUnited States
-
San Diego State UniversityRecruitingPostprandial Hyperglycemia | Postprandial Glycemic Response | Postprandial InsulinUnited States
-
Hospital de Santo EspíritoEuropean UnionCompleted
-
University of TurkuCompletedPostprandial GlycemiaFinland
Clinical Trials on Blackcurrant extract (low dose)
-
Brand's Suntory AsiaTaipei Medical University Shuang Ho HospitalNot yet recruiting
-
Greenyn Biotechnology Co., Ltd.Taipei Medical UniversityRecruitingDiabetes | Metabolic DiseaseTaiwan
-
Centro de Estudios en Alimentos ProcesadosQuadram Institute Bioscience; University of TalcaCompletedCardiovascular DiseasesChile
-
University of ChichesterCompletedno ConditionsUnited Kingdom
-
Natural Wellness EgyptCompletedType2 Diabetes MellitusEgypt
-
University of Mary Hardin-BaylorIndus Biotech Ltd. Pvt.CompletedInflammation | Muscle DamageUnited States
-
Nathaniel JenkinsCompletedAcute Physiological Effects of Organic Guayusa ExtractUnited States
-
Stratum NutritionKitozymeCompletedCardiovascularUnited States, Canada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Howard University; Prostate Cancer Clinical Trials ConsortiumCompleted
-
National Research Council, SpainUniversidad Católica San Antonio de Murcia; The Scientific and Technological...Completed